Based on the univariate Cox regression analysis, high SESN2 expression was associated with a poorer outcome in gliomas (HR = 2.464, 95% confidence interval (CI), 1.912–3.175; p < 0.001). This evidence concerns the gene SESN2 and central nervous system cancer.